AGENUS INC, a prominent player in the health care biotechnology sector, has recently filed an EFFECT form with the Securities and Exchange Commission (SEC). This filing confirms that the company’s S-3 registration statement has become effective as of July 27, 2026. The S-3 registration is a significant milestone for publicly traded companies, allowing them to issue securities more efficiently.
AGENUS INC, incorporated in Delaware, is headquartered in Lexington, United States. The company specializes in immuno-oncology, focusing on the development of checkpoint antibodies and other synergistic agents aimed at providing curative outcomes for patients globally. This strategic focus underscores AGENUS’s commitment to advancing cancer treatment through innovative biotechnological solutions.
The company’s stock is traded on the Nasdaq, where it has experienced notable fluctuations over the past year. As of July 26, 2026, the close price of AGENUS’s stock was $6.13. The stock reached its 52-week high of $8.70 on July 12, 2026, and its 52-week low of $2.71 on February 4, 2026. These figures reflect the dynamic nature of the biotechnology sector and the market’s response to AGENUS’s ongoing developments and strategic initiatives.
With a market capitalization of approximately $249 million, AGENUS INC maintains a price-to-earnings ratio of 3.414. This valuation metric provides insight into the company’s financial health and investor sentiment, indicating a moderate level of earnings relative to its stock price.
AGENUS INC was originally incorporated as ANTIGENICS INC in 1999, marking its transition to its current name and identity. The company’s initial public offering (IPO) took place on February 4, 2000, establishing its presence in the public market and setting the stage for its growth and evolution in the biotechnology industry.
For those interested in learning more about AGENUS’s work and offerings, further information is available on their website at www.agenusbio.com . The company continues to focus on its mission to enhance patient outcomes through cutting-edge biotechnological advancements, reinforcing its position as a key player in the immuno-oncology field.
